Key points are not available for this paper at this time.
Sulfur-based chiral centers play a critical role in drug discovery yet pose significant challenges in achieving precise stereochemical control. Sulfinamides, serving as versatile intermediates and chiral auxiliaries, have traditionally required multistep synthesis or auxiliary-dependent strategies. Recent advances using N -sulfinyltritylamine (TrNSO) enabled catalytic arylative additions; however, stereoselective alkylative approaches remain underdeveloped, likely due to the highly reactive alkyl radical intermediate. Herein, we report a cobalt-catalyzed reductive addition strategy for direct enantioselective C(sp 3 )–S bond formation between TrNSO and unactivated alkyl halides. Leveraging an unprecedented 8-Quinox cobalt catalyst, this method delivers alkyl-substituted sulfinamides with broad substrate scope, excellent functional group tolerance, and high enantioselectivity. The protocol is further extended to a cascade addition/cyclization sequence, facilitating the efficient synthesis of enantioenriched sultims. DFT calculations reveal stereochemical control arises from selective alkyl radical addition orchestrated by the chiral cobalt catalyst.
Liu et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: